About the Authors
- Edward G. Meloni
-
* E-mail: emeloni@mclean.harvard.edu
Affiliation Department of Psychiatry, Harvard Medical School and McLean Hospital, Belmont, Massachusetts, United States of America
- Timothy E. Gillis
-
Affiliation Department of Psychiatry, Harvard Medical School and McLean Hospital, Belmont, Massachusetts, United States of America
- Jasmine Manoukian
-
Affiliation Department of Psychiatry, Harvard Medical School and McLean Hospital, Belmont, Massachusetts, United States of America
- Marc J. Kaufman
-
Affiliation Department of Psychiatry, Harvard Medical School and McLean Hospital, Belmont, Massachusetts, United States of America
Competing Interests
The authors have read the journal's policy and the following authors of this manuscript have the following competing interests: Drs. Meloni and Kaufman disclose that they are co-inventors on intellectual property (provisional patent) owned by The McLean Hospital Corporation covering the therapeutic use of xenon for PTSD. Currently the patent has been converted from a provisional patent and is awaiting review by the patent office. Hence, it is in a state of “patent pending.” The application is PCT Application No. PCT/US13/74007 filed on December 10, 2013. This pending patent does not alter the authors' adherence to all PLOS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: EGM MJK. Performed the experiments: EGM. Analyzed the data: JM. Contributed reagents/materials/analysis tools: TEG. Contributed to the writing of the manuscript: EGM MJK.